AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28416587
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (fluticasone furoate 100 µg and vilanterol 25 µg)
Trial: 23315402
Drug: Oral feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feedback with written information
Trial: 23315402
Drug: Oral feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feedback only
Trial: 21977857
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine plus rehabilitation
Trial: 21977857
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine plus acupuncture
Trial: 21977857
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine and acupuncture plus rehabilitation
Trial: 21977857
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine piracetam
Trial: 17074146
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (aspirin, clopidogrel)
Trial: 15639697
Drug: Rosuvastatin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 80 mg/d alone (n = 69)
Trial: 15639697
Drug: Rosuvastatin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 80 mg/d plus cholestyramine 16 g/d (n = 75)
Trial: 15639697
Drug: Rosuvastatin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 80 mg/d plus cholestyramine 16 g/d
Trial: 15639697
Drug: Rosuvastatin 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 80 mg/d alone
Trial: 11508705
Drug: Caffeine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (6 mg/kg) in rats
Trial: 11508705
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg/kg) in athletes
Trial: 3325092
Drug: Nocturnal dosing
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nocturnal dosing with levodopa
Trial: 20919606
Drug: Clindamycin phosphate
RxNorm normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin phosphate 7.2%‐tretinoin 0.025% gel (CTG) combination product
Trial: 20919606
Drug: Separate daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate daily applications of clindamycin phosphate gel 1% and tretinoin cream 0.025% (C gel + T cream)
Trial: 12538365
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 4 mg kg(‐1) h(‐1) (Group A)
Trial: 12538365
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 5 mg kg(‐1) h(‐1) (Group B)
Trial: 12538365
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion at 6 mg kg(‐1) h(‐1) (Group C)
Trial: 6234015
Drug: Isotretinoin (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotretinoin (0.05 mg/kg/day)
Trial: 6234015
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (5 mg daily)
Trial: 26748629
Drug: Pancrelipase replacement
RxNorm normalized name: Pancrelipase amylase
DrugBank: Pancrelipase amylase (DB11065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancrelipase replacement therapy
Trial: 26748629
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to pancrelipase replacement therapy upon NAFLD diagnosis in control group
Trial: 16776752
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine therapy
Trial: 22413808
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose > 10 mmol/l at week 6/8 or week 12
Trial: 22413808
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma glucose < 8.9 mmol/l at week 6/8 or week 12
Trial: 15126526
Drug: L-T(4) replacement
RxNorm normalized name: L-3972-T
DrugBank: L-3972-T (DB17441)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T(4) replacement therapy
Trial: 3388180
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia with parenteral morphine (GA group)
Trial: 3388180
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia combined with epidural bupivacaine and epidural morphine (EP group)
Trial: 30142849
Drug: Ultralow-dose CT
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultralow-dose CT (ULDCT)
Trial: 30142849
Drug: Standard low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard low-dose CT (LDCT)
Trial: 23887766
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of 12 mg triamcinolone acetonide at the end of surgery
Trial: 23887766
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no steroid injection)
Trial: 20002501
Drug: Fluconazole (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (800 mg/day)
Trial: 12829925
Drug: Low-dose calcitriol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose calcitriol
Trial: 12829925
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard immunosuppressive therapy)
Trial: 9715320
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with antibiotics
Trial: 9199120
Drug: Combined method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined method (surgery and radiotherapy) with moderate postoperative dose of irradiation (5500-6000 cGy)
Trial: 9199120
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated by radical neck dissection (RND), modified neck dissection (MND), or regional modified neck dissection (RMND) with moderate postoperative dose of irradiation (5000-5500 cGy)
Trial: 1946180
Drug: Ordinary syringe
RxNorm normalized name: ordinary salt combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary syringe (4 IU/ml)
Trial: 1946180
Drug: Injection pen
RxNorm normalized name: Albiglutide 30 mg powder for solution for injection pen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection pen (12 IU/ml)
Trial: 21175276
Drug: Computer-guided GIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-guided GIN therapy (GINCS)
Trial: 21175276
Drug: Manually controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manually controlled GIN therapy
Trial: 19724043
Drug: Mass distribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass distribution of oral azithromycin (1 g for adults, 20 mg/kg for children) administered to communities with over 80% coverage for children aged 1 to 9 years.
Trial: 19724043
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment for 1 year) with 18,498 participants.
Trial: 12714876
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day lercanidipine (n = 48)
Trial: 12714876
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day amlodipine (n = 44)
Trial: 1909286
Drug: Persumbran (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persumbran (25 mg dipyridamole + 10 mg oxazepam)
Trial: 24836352
Drug: Enalapril/lercanidipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril/lercanidipine combination (20/10 mg)
Trial: 24836352
Drug: Lercanidipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine (10 mg)
Trial: 17589951
Drug: Two-week triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-week triple therapy for H pylori eradication
Trial: 12209373
Drug: Riboflavin supplementation
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin supplementation (1.6 mg/day) for 12 weeks
Trial: 12209373
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplementation (400 micro g/day) for 6 weeks followed by folic acid and riboflavin (1.6 mg/day) for 12 weeks
Trial: 8691860
Drug: Methylprednisolone 25
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone 25 mg/kg body weight
Trial: 1809790
Drug: 2% cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% cyclosporine ophthalmic ointment (dosed once, twice, or thrice daily for 14 days)
Trial: 6135720
Drug: Estazolam 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam 0.25 mg
Trial: 6135720
Drug: Estazolam 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam 0.5 mg
Trial: 6135720
Drug: Estazolam 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estazolam 1.0 mg
Trial: 31256191
Drug: Active shoulder
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active shoulder exercise with a sling suspension system
Trial: 25203806
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 13 to 15 mg/kg/d for 4 weeks
Trial: 19256150
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g vegetable protein diet
Trial: 19256150
Drug: Vegetable protein
RxNorm normalized name: Hydrogenated Vegetable Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vegetable protein diet plus 3 g/day of oral kanamycin
Trial: 24370801
Drug: Low-dose fentanyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fentanyl
Trial: 20438741
Drug: Modified sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified sham feeding (MSF) with cherry Kool Aid solutions sweetened with aspartame at concentrations of 0, 0.01, 0.03, 0.08 and 0.28%
Trial: 18434268
Drug: Lornoxicam i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam i.v. 8 mg 20 min before incision (Group PRE)
Trial: 18434268
Drug: Saline i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline i.v. 20 mins before incision and lornoxicam i.v. 8 mg after skin closure (Group POST)
Trial: 16435640
Drug: Submucosal-administered meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal-administered meperidine (0.5 mg/lb) with oral hydroxyzine (0.5 mg/lb)
Trial: 16435640
Drug: Oral-administered meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-administered meperidine (1 mg/lb) with oral hydroxyzine (0.5 mg/lb)
Trial: 16435640
Drug: Submucosal-administered meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submucosal-administered meperidine (0.5 mg/lb)
Trial: 16435640
Drug: Oral-administered meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-administered meperidine (1 mg/lb)
Trial: 12805247
Drug: 500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/day vitamin C
Trial: 12805247
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day vitamin C
Trial: 11568777
Drug: Raloxifene 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 150 mg daily
Trial: 10374220
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.625 mg daily
Trial: 1800394
Drug: Nifedipine alone
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine alone (15-60 mg)
Trial: 1800394
Drug: Nifedipine in
RxNorm normalized name: nifedipine Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine in combination with dilazep (50 mg three times a day)
Trial: 1800394
Drug: Nifedipine alone
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine alone and in combination with dilazep
Trial: 6401172
Drug: NTG spray
RxNorm normalized name: nitroglycerin Mucosal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG spray 0.8 mg
Trial: 15811205
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (TLA and TIM)
Trial: 11222785
Drug: IVIg (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (1 g/kg)
Trial: 9429051
Drug: Perphenazine 70
RxNorm normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perphenazine 70 micrograms.kg‐1 up to 5 mg
Trial: 8508192
Drug: 2.5‐mg boron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5‐mg boron supplement
Trial: 3543767
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg, four times daily for six weeks, initiated during the third trimester)
Trial: 3543767
Drug: Placebo (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (four times daily for six weeks)
Trial: 3543767
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg, four times daily for six weeks, initiated during the second trimester)
Trial: 3543767
Drug: Clindamycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (150 mg, four times daily for six weeks)
Trial: 21472661
Drug: PF-734200 2
RxNorm normalized name: chloroprocaine
DrugBank: Chloroprocaine (DB01161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-734200 2 mg
Trial: 21472661
Drug: PF-734200 5
RxNorm normalized name: haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-734200 5 mg
Trial: 21472661
Drug: PF-734200 10
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-734200 10 mg
Trial: 21472661
Drug: PF-734200 20
RxNorm normalized name: acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-734200 20 mg
Trial: 18784341
Drug: gD2 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gD2 DNA vaccine (100 microg, 300 microg, 1,000 microg, or 3,000 microg)
Trial: 18784341
Drug: gD2 DNA
RxNorm normalized name: TOXOPLASMA GONDII DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gD2 DNA vaccine (3,000 microg)
Trial: 14634493
Drug: Ondansetron 16
RxNorm normalized name: ondansetron 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 16 microg/kg twice daily
Trial: 30402880
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of M281 (anti-FcRn antibody) at doses of 15 or 30 mg/kg
Trial: 30402880
Drug: M281 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M281 (all doses)
Trial: 22289752
Drug: Anti-neutrophil cytoplasmic
RxNorm normalized name: Anti-neutrophil cytoplasmic antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-neutrophil cytoplasmic antibody (ANCA) in the acute phase of Kawasaki disease
Trial: 22289752
Drug: Anti-neutrophil cytoplasmic
RxNorm normalized name: Anti-neutrophil cytoplasmic antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-neutrophil cytoplasmic antibody (ANCA) in the recovery phase of Kawasaki disease
Trial: 22289752
Drug: Anti-neutrophil cytoplasmic
RxNorm normalized name: Anti-neutrophil cytoplasmic antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-neutrophil cytoplasmic antibody (ANCA) status in Kawasaki disease
Trial: 18198650
Drug: Qiangyue Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qiangyue Cream (QYC)
Trial: 18198650
Drug: Halometasone cream
RxNorm normalized name: halometasone
DrugBank: Halometasone (DB13728)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halometasone cream
Trial: 2212452
Drug: Imidazole salicylate
RxNorm normalized name: imidazole salicylate
DrugBank: Imidazole salicylate (DB13860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidazole salicylate 750 mg three times daily
Trial: 20637539
Drug: PSA >
RxNorm normalized name: Prostate-Specific Antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA > or = 3.0 ng/ml
Trial: 17761004
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group receiving inactive ultrasound and gentle application of an inert gel over the shoulder region.
Trial: 8073240
Drug: Pharmaceutical treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical treatments
Trial: 2799271
Drug: Ferric-aluminum-fluoride solution
RxNorm normalized name: aluminum fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferric-aluminum-fluoride solution (FeAlF)
Trial: 1107648
Drug: Ocusert drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocusert drug delivery system
Trial: 31090673
Drug: Acute aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute aspirin (81 mg; single-dose)
Trial: 31090673
Drug: Chronic aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic aspirin (81 mg; 14 days)
Trial: 25650370
Drug: Perhexiline 200
RxNorm normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perhexiline 200 mg for 1 month
Trial: 10830255
Drug: Home oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home oxygen therapy
Trial: 19382032
Drug: 5 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg/day peroral iron for 2 months
Trial: 17998507
Drug: Ranibizumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (both doses)
Trial: 28303471
Drug: Neutral pH
RxNorm normalized name: Gelato Neutral pH 2 % Oral Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral pH bleaching gel (Pola Office+)
Trial: 28303471
Drug: Acid pH
RxNorm normalized name: Acid phosphatase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acid pH bleaching gel (Pola Office)
Trial: 24149738
Drug: 300 mg·d(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg·d(‐1) magnesium oxide supplementation
Trial: 17908741
Drug: Combined vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined vitamin A and zinc supplement
Trial: 14726116
Drug: Controlled Release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled Release (CR) tablets
Trial: 14726116
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) tablets
Trial: 11331213
Drug: l‐T4 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐T4 administration (100 microg/day)
Trial: 9330779
Drug: BMS‐181101 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐181101 administered with food
Trial: 9330779
Drug: BMS‐181101 administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS‐181101 administered without food
Trial: 7970996
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg intravenous allopurinol
Trial: 7970996
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg intravenous allopurinol
Trial: 2912911
Drug: Treatment density
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment density (repeating photocoagulation)
Trial: 238810
Drug: Loxapine succinate
RxNorm normalized name: Loxapine Succinate
DrugBank: Loxapine (DB00408)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loxapine succinate (LOX) 40-65 mg/day, b.i.d. schedule
Trial: 238810
Drug: Trifluoperazine hydrochloride
RxNorm normalized name: Trifluoperazine Hydrochloride
DrugBank: Trifluoperazine (DB00831)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trifluoperazine hydrochloride (TFP) appropriate dosage
Trial: 28300867
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg bid